ER POSITIVE BREAST CANCER
Clinical trials for ER POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets Hard-to-Treat cancers with AKT1 mutation
Disease control OngoingThis early-stage study tests an experimental pill, ATV-1601, in adults with advanced solid tumors or certain breast cancers that have a specific AKT1 gene change. The main goals are to find a safe dose and check how the drug moves through the body. About 134 participants will tak…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New drug combo aims to keep ER+ breast cancer in check
Disease control OngoingThis study tests a drug called ribociclib, combined with standard hormone therapy, for people with ER-positive breast cancer. The goal is to see if this combination can clear tumor DNA from the blood and help control the disease over time. About 120 postmenopausal women with earl…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
Promising breast cancer drug trial pulled before starting
Disease control TerminatedThis study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Danish Breast Cancer Cooperative Group • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control OngoingThis study tests a combination of two drugs, lenvatinib and letrozole, given before surgery to postmenopausal women with a common type of breast cancer (hormone receptor positive). The goal is to see if the drugs can shrink the tumor enough to improve surgical outcomes. About 40 …
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC
-
New study explores letrozole's effects on breast cancer before surgery
Disease control OngoingThis study tests the drug letrozole in postmenopausal women with early-stage ER+ breast cancer. Participants take letrozole for 4 to 24 weeks before surgery to see how the tumor changes and to check if they take the medication as prescribed. The goal is to improve treatment for t…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC
-
Blood test may signal when to switch breast cancer treatment earlier
Knowledge-focused OngoingThis phase 2 trial tests whether a blood test that detects tumor DNA (ctDNA) can help doctors decide when to switch treatments in people with metastatic breast cancer. The goal is to see if switching therapy at the first sign of molecular progression, before symptoms or scans sho…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:56 UTC